Study guide

10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

Key Takeaways Explain This Topic AI

A prognostic factor predicts outcome regardless of treatment (for example, stage or Breslow thickness); a predictive factor predicts benefit from a specific therapy (for example, HER2 for trastuzumab, or RAS mutation for lack of benefit from anti-EGFR antibodies).

HPV-mediated (p16-positive) oropharyngeal cancer has its own AJCC 8th edition staging because of its much better prognosis than p16-negative disease.

ER Summary [3827] is coded 0 (negative, less than 1%), 1 (positive), 7 (test ordered, results not in chart) or 9 (not documented or unknown); PR Summary is [3915] and HER2 Overall Summary is [3855].

Breslow Tumor Thickness [3817] is recorded in millimeters to the nearest tenth (for example, 0.8), and in situ melanoma is coded XX.9.

Tumor Deposits [3934] is coded 00 for none, 01–99 for the exact number, X1 for 100 or more, and X2 when deposits are present but the number is unknown.

Last updated: September 2026

Prognostic versus predictive

Type Definition Examples

Prognostic Predicts the likely course of disease, independent of treatment Stage, grade, Breslow thickness, lymphovascular invasion, Ki-67, cytogenetic risk group

Predictive Predicts benefit (or lack of benefit) from a specific treatment ER/PR (endocrine therapy), HER2 (HER2-targeted drugs), KRAS/NRAS (anti-EGFR antibodies), EGFR/ALK/ROS1 (tyrosine kinase inhibitors), PD-L1 and MSI-H (immunotherapy)

  • Both Many markers are both HER2, MSI-H/dMMR, BRAF V600E
  • The markers named in the ODS outline
  • HPV (human papillomavirus)

Where: oropharynx (tonsil, base of tongue), cervix, anus, vulva, vagina, penis.

Testing: p16 IHC is the usual surrogate for high-risk HPV in the oropharynx; HPV DNA or RNA testing confirms it.

Why it matters: AJCC 8th edition stages HPV-mediated (p16+) oropharyngeal cancer in a separate chapter from p16-negative disease, because HPV-related tumors have much better survival. The staging schema, and therefore the SSDIs and stage group, depend on this result.

KRAS (and NRAS, BRAF)

Where: colorectal, lung and pancreatic cancer.

Why it matters: in metastatic colorectal cancer, RAS-mutated tumors (KRAS or NRAS) do not benefit from anti-EGFR antibodies (cetuximab, panitumumab), which makes KRAS a predictive marker. BRAF V600E in colorectal cancer carries a poor prognosis. In lung cancer, KRAS G12C has its own targeted drugs.

HER-2 (ERBB2)

Where: breast and gastric/GE junction cancer, among others.

Testing: IHC (0, 1+, 2+, 3+) with reflex in situ hybridization for 2+ results (see Section 10.3).

Why it matters: HER2-positive tumors are more aggressive untreated but respond to HER2-targeted therapy (trastuzumab, pertuzumab, antibody-drug conjugates). In breast cancer, HER2 status is required to assign the AJCC prognostic stage group .

Other high-yield indicators

Site Indicators

Breast ER, PR, HER2, grade, multigene signatures (21-gene recurrence score; RS below 11 places some T1–T2 N0 ER+ HER2− tumors in prognostic stage IA), Ki-67

Colorectal MSI/MMR, KRAS, NRAS, BRAF, CEA, tumor deposits, circumferential resection margin, perineural invasion

  • Lung EGFR, ALK, ROS1, BRAF, KRAS G12C, PD-L1, separate tumor nodules, visceral pleural invasion
  • Prostate PSA, Gleason patterns and score, Grade Group, number of positive cores
  • Melanoma Breslow thickness, ulceration, mitotic rate, LDH
  • Testis Serum AFP, beta-hCG and LDH (the AJCC S category)
  • CNS IDH mutation, 1p/19q codeletion, MGMT methylation
  • Myeloma and leukemia Cytogenetic risk, for example del(17p) and t(4;14) in myeloma, or FLT3 and NPM1 in AML
  • Site-Specific Data Items (SSDIs)

SSDIs are defined in the NAACCR Site-Specific Data Item Manual . They took effect for 2018 diagnoses, replacing the Collaborative Stage site-specific factors. Each SSDI belongs to one or more schemas . The registry software derives the schema from the primary site, histology, and sometimes a schema discriminator, and then displays only the SSDIs that apply.

Codes use consistent conventions: actual values or categories, plus special codes. X8 (or XX.8) means not applicable , meaning the information is not collected for this schema, and it will fail edits if a standard setter requires the item. X9 (or XX.9) means not documented or unknown . Always use the SSDI Manual definitions for each item.

Verified SSDI examples

SSDI Codes

Estrogen Receptor Summary [3827] 0 = ER negative (0.0% or less than 1%); 1 = ER positive; 7 = test ordered, results not in chart; 9 = not documented, cannot be determined, or unknown if assessed

Progesterone Receptor Summary [3915] and HER2 Overall Summary [3855] Summary interpretations that feed the AJCC breast prognostic stage

Breslow Tumor Thickness [3817] Millimeters to the nearest tenth: 0.0 = no mass or tumor found; 0.1 = more than 0.0 and up to 0.1 mm; 0.2–99.9 = the measurement; XX.1 = 100 mm or larger; A0.1–A9.9 = stated as "at least" that value; AX.0 = stated as greater than 9.9 mm; XX.8 = not applicable; XX.9 = not documented, microinvasion without a depth, in situ melanoma , or unknown

Tumor Deposits [3934] (colorectal) 00 = none; 01–99 = exact number; X1 = 100 or more; X2 = present, number unknown; X8 = not applicable; X9 = not documented, not assessed, or no resection

Worked example: the pathology report says "Breslow depth 0.75 mm, ulceration present." AJCC melanoma thickness is measured to the nearest 0.1 mm, so 0.75 mm rounds to 0.8 mm . Breslow Tumor Thickness is coded 0.8 , and Ulceration is coded as present. The resulting T category is T1b, since a tumor 0.8–1.0 mm, or under 0.8 mm with ulceration, is T1b.

"Data items required by standard setters"

Every NAACCR item has a required status for each standard setter (CoC, SEER, NPCR and the Canadian Council of Cancer Registries). For example, the NAACCR SSDI pages list ER Summary [3827] as "Required, site specific" for NPCR, CoC and SEER. Tumor Deposits [3934] is required by CoC and SEER, with no NPCR recommendation. Key points:

STORE defines what CoC programs must collect and submit to the NCDB. The SEER manual and NPCR requirements define what central registries collect, and state rules may add items.

An item "required" by a standard setter must be coded, with unknown codes used only when the information truly is not available. An "X8, not applicable" code in a required field fails edits.

Dates: NAACCR transmits dates as CCYYMMDD , and the unknown parts are left blank . For example, June 2026 with an unknown day is transmitted as 202606 followed by blanks. The 99 and 99999999 convention belonged to the pre-2010 traditional format. Date flag items explain why a date is blank (for example, no information, or not applicable).

Loading diagram... From test result to registry item